Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
2023 · Blood Cancer Journal · 29 citations
https://doi.org/10.1038/s41408-023-00830-w
E
Edward Ayoub
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
73
Papers
447
Citations
9
h-index
9
i10-index
Edward Ayoub is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Protein Degradation and Inhibitors & Cancer-related Molecular Pathways. The author has an h-index of 9, co-authored 63 publications.
ORCID: 0000-0003-1321-0114Papers by this author
worksMdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage
2023 · Cell Death and Disease · 4 citations
https://doi.org/10.1038/s41419-023-05844-7
Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage
2023 · Research Square · 0 citations
https://doi.org/10.21203/rs.3.rs-2544760/v1
ChIP-seq in the murine leukemic cell line Da-1
2018 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.7043468
Perkins ChIP-seq in DA-1
2018 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.7043468.v1
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway
2025 · Research Square · 0 citations
https://doi.org/10.21203/rs.3.rs-6017610/v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat